Applicants,Chemical_Name,Funding_requested_for,Pharmaceutical,Priority_List,Schedules,Therapeutic_group
GLAXOSMITHKLINE NZ LIMITED,Mepolizumab,"Eosinophilic asthma, remove requirement for Asthma Control Test (ACT)",Mepolizumab (Nucala),Options for investment,Community and Hospital,Oncology Agents and Immunosuppressants
